{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:21:50Z","timestamp":1787916110041,"version":"build-2784847793"},"reference-count":137,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Italian Ministry of University and Research","award":["2017483NH8"],"award-info":[{"award-number":["2017483NH8"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,22]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Drug repurposing involves the identification of new applications for existing drugs at a lower cost and in a shorter time. There are different computational drug-repurposing strategies and some of these approaches have been applied to the coronavirus disease 2019 (COVID-19) pandemic. Computational drug-repositioning approaches applied to COVID-19 can be broadly categorized into (i) network-based models, (ii) structure-based approaches and (iii) artificial intelligence (AI) approaches. Network-based approaches are divided into two categories: network-based clustering approaches and network-based propagation approaches. Both of them allowed to annotate some important patterns, to identify proteins that are functionally associated with COVID-19 and to discover novel drug\u2013disease or drug\u2013target relationships useful for new therapies. Structure-based approaches allowed to identify small chemical compounds able to bind macromolecular targets to evaluate how a chemical compound can interact with the biological counterpart, trying to find new applications for existing drugs. AI-based networks appear, at the moment, less relevant since they need more data for their application.<\/jats:p>","DOI":"10.1093\/bib\/bbaa288","type":"journal-article","created":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T19:06:53Z","timestamp":1601838413000},"page":"726-741","source":"Crossref","is-referenced-by-count":158,"title":["A review on drug repurposing applicable to COVID-19"],"prefix":"10.1093","volume":"22","author":[{"given":"Serena","family":"Dotolo","sequence":"first","affiliation":[{"name":"University of Salerno"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Marabotti","sequence":"additional","affiliation":[{"name":"University of Salerno"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Facchiano","sequence":"additional","affiliation":[{"name":"Institute of Food Sciences, CNR Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Tagliaferri","sequence":"additional","affiliation":[{"name":"Artificial Intelligence, Statistical Pattern Recognition, Clustering, Biomedical imaging and Bioinformatics"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"2021032314263124600_ref1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","article-title":"Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines","volume":"19","author":"Jin","year":"2014","journal-title":"Drug Discov Today"},{"key":"2021032314263124600_ref2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1568026615666150112103510","article-title":"Computational and experimental advances in drug repositioning for accelerated therapeutic stratification","volume":"15","author":"Shameer","year":"2015","journal-title":"Curr Top Med Chem"},{"key":"2021032314263124600_ref3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.drudis.2016.10.008","article-title":"Drug repurposing by integrated literature mining and drug-gene-disease triangulation","volume":"22","author":"Sun","year":"2017","journal-title":"Drug Discov Today"},{"key":"2021032314263124600_ref4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.biopha.2018.11.127","article-title":"An update on Drug Repurposing: Re-written saga of the drugs fate","volume":"110","author":"Gns","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"2021032314263124600_ref5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17460441.2020.1704729","article-title":"Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics","volume":"15","author":"Talevi","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"2021032314263124600_ref6","first-page":"157","article-title":"Drug repositioning: concept, classification, methodology, and importance in rare\/orphans and neglected diseases","volume":"8","author":"de Oliveira","year":"2018","journal-title":"J Appl Pharm Sci"},{"key":"2021032314263124600_ref7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1087057114563024","article-title":"In vitro screening for drug repositioning","volume":"20","author":"Wilkinson","year":"2015","journal-title":"J Biomol Screen"},{"key":"2021032314263124600_ref8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fonc.2017.00273","article-title":"Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics","volume":"7","author":"Hernandez","year":"2017","journal-title":"Front Oncol"},{"key":"2021032314263124600_ref9","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaa003","article-title":"Exploration of databases and methods supporting drug repurposing: a comprehensive survey","volume-title":"Brief Bioinform","author":"Tanoli","year":"2020"},{"key":"2021032314263124600_ref10","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int J Biol Sci"},{"key":"2021032314263124600_ref11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.drudis.2012.07.014","article-title":"Transcriptional data: a new gateway to drug repositioning?","volume":"18","author":"Iorio","year":"2013","journal-title":"Drug Discov Today"},{"key":"2021032314263124600_ref12","doi-asserted-by":"crossref","first-page":"117652","DOI":"10.1016\/j.lfs.2020.117652","article-title":"In silico studies on therapeutic agents for COVID-19: Drug repurposing approach","volume":"252","author":"Shah","year":"2020","journal-title":"Life Sci"},{"key":"2021032314263124600_ref13","first-page":"1","article-title":"Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2-O-ribose methyltransferase","author":"Khan","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drudis.2018.06.012","article-title":"Renovation as innovation: is repurposing the future of drug discovery research?","volume":"24","author":"Neuberger","year":"2019","journal-title":"Drug Discov Today"},{"key":"2021032314263124600_ref15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/bib\/bbv020","article-title":"A survey of current trends in computational drug repositioning","volume":"17","author":"Li","year":"2016","journal-title":"Brief Bioinform"},{"key":"2021032314263124600_ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1764392","article-title":"Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2","author":"Al-Khafaji","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.12793\/tcp.2019.27.2.59","article-title":"A review of computational drug repurposing","volume":"27","author":"Park","year":"2019","journal-title":"Transl Clin Pharmacol"},{"key":"2021032314263124600_ref18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2217\/pgs-2018-0036","article-title":"Computational functional genomics-based approaches in analgesic drug discovery and repurposing","volume":"19","author":"Lippmann","year":"2018","journal-title":"Pharmacogenomics"},{"key":"2021032314263124600_ref19","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int J Biol Sci"},{"key":"2021032314263124600_ref20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.drudis.2018.01.018","article-title":"A bibliometric review of drug repurposing","volume":"23","author":"Baker","year":"2018","journal-title":"Drug Discov Today"},{"key":"2021032314263124600_ref21","doi-asserted-by":"crossref","first-page":"105984","DOI":"10.1016\/j.ijantimicag.2020.105984","article-title":"Combating devastating COVID-19 by drug repurposing","volume":"56","author":"Pawar","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2021032314263124600_ref22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ajog.2020.03.021","article-title":"Coronavirus disease 2019 (COVID-19) pandemic and pregnancy","volume":"222","author":"Dashraath","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"2021032314263124600_ref23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven prote-ase inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"2021032314263124600_ref24","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"2021032314263124600_ref25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.virusres.2014.11.021","article-title":"Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis","volume":"202","author":"Millet","year":"2015","journal-title":"Virus Res."},{"key":"2021032314263124600_ref26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.virol.2017.11.012","article-title":"Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry","volume":"517","author":"Shirato","year":"2018","journal-title":"Virology"},{"key":"2021032314263124600_ref27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"2021032314263124600_ref28","doi-asserted-by":"crossref","first-page":"165878","DOI":"10.1016\/j.bbadis.2020.165878","article-title":"Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach","volume":"1866","author":"Naqvi","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2021032314263124600_ref29","doi-asserted-by":"crossref","first-page":"982","DOI":"10.3390\/jcm9040982","article-title":"Master Regulator Analysis of the SARS-CoV-2\/Human Interactome","volume":"9","author":"Guzzi","year":"2020","journal-title":"J Clin Med"},{"key":"2021032314263124600_ref30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"2021032314263124600_ref31","doi-asserted-by":"crossref","first-page":"102433","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of corona-virus disease (COVID-19) outbreak","volume":"109","author":"Rothan","year":"2020","journal-title":"J Autoimmun"},{"key":"2021032314263124600_ref32","first-page":"372","article-title":"Virology, epidemiology, pathogenesis, and control of COVID-19","volume-title":"Viruses","author":"Jin","year":"2020"},{"key":"2021032314263124600_ref33","doi-asserted-by":"crossref","first-page":"149762","DOI":"10.1155\/2012\/149762","article-title":"Traditional chinese medicine-based network pharmacology could lead to new multicompound drug discovery","volume":"2012","author":"Li","year":"2012","journal-title":"Evid Based Complement Alternat Med"},{"key":"2021032314263124600_ref34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov"},{"key":"2021032314263124600_ref35","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/CM9.0000000000000797","article-title":"Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model","volume":"133","author":"Fan","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"2021032314263124600_ref36","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1109\/TCBB.2014.2325031","article-title":"Network-based drug-target interaction prediction with probabilistic soft logic","volume":"11","author":"Fakhraei","year":"2014","journal-title":"IEEE\/ACM Trans Comput Biol Bioinform"},{"key":"2021032314263124600_ref37","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1109\/TCBB.2013.62","article-title":"Network-based drug ranking and repositioning with respect to DrugBank therapeutic categories","volume":"10","author":"Re","year":"2013","journal-title":"IEEE\/ACM Trans Comput Biol Bioinform"},{"key":"2021032314263124600_ref38","doi-asserted-by":"crossref","first-page":"130620","DOI":"10.1155\/2015\/130620","article-title":"Network-based inference methods for drug repositioning","volume":"2015","author":"Chen","year":"2015","journal-title":"Comput Math Methods Med"},{"key":"2021032314263124600_ref39","article-title":"Pathway-based drug repositioning using causal inference","volume":"14 Suppl 16","author":"Li","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"2021032314263124600_ref40","doi-asserted-by":"crossref","first-page":"e87864","DOI":"10.1371\/journal.pone.0087864","article-title":"Construction of drug network based on side effects and its application for drug repositioning","volume":"9","author":"Ye","year":"2014","journal-title":"PLoS One"},{"key":"2021032314263124600_ref41","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.3390\/ijms21072657","article-title":"A review of SARS-CoV-2 and the ongoing clinical trials","volume":"21","author":"Tu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2021032314263124600_ref42","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/phar.2398","article-title":"Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019","volume":"40","author":"Barlow","year":"2020","journal-title":"Pharmacotherapy"},{"key":"2021032314263124600_ref43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12967-020-02405-w","article-title":"COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection","volume":"18","author":"Messina","year":"2020","journal-title":"J Transl Med"},{"key":"2021032314263124600_ref44","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1038\/s41467-020-17189-2","article-title":"Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing","volume":"11","author":"Sadegh","year":"2020","journal-title":"Nat Commun"},{"key":"2021032314263124600_ref45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/978-1-61779-361-5_16","article-title":"Protein complex prediction with RNSC","volume":"804","author":"King","year":"2012","journal-title":"Methods Mol Biol."},{"key":"2021032314263124600_ref46","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/1471-2105-10-283","article-title":"RRW: repeated random walks on genome-scale protein networks for local cluster discovery","volume":"10","author":"Macropol","year":"2009","journal-title":"BMC Bioinformatics"},{"key":"2021032314263124600_ref47","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/bioinformatics\/btx043","article-title":"Identification of protein complexes by integrating multiple alignment of protein interaction networks","volume":"33","author":"Ma","journal-title":"Bioinformatics"},{"key":"2021032314263124600_ref48","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nmeth.1938","article-title":"Detecting overlapping protein complexes in protein-protein interaction networks","volume":"9","author":"Nepusz","year":"2012","journal-title":"Nat Methods"},{"key":"2021032314263124600_ref49","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2105-4-2","article-title":"An automated method for finding molecular complexes in large protein interaction networks","volume":"4","author":"Bader","year":"2003","journal-title":"BMC Bioinformatics"},{"issue":"17","key":"2021032314263124600_ref50","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1093\/bioinformatics\/btw228","article-title":"Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm","volume":"32","author":"Luo","journal-title":"Bioinformatics"},{"key":"2021032314263124600_ref51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000641","article-title":"Associating Genes and Protein Complexes with Disease via Network Propagation","volume":"6","author":"Vanunu","year":"2010","journal-title":"PLoS Comput Biol"},{"key":"2021032314263124600_ref52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.artmed.2014.11.003","article-title":"DrugNet: network-based drug-disease prioritization by integrating heterogeneous data","volume":"63","author":"Mart\u00ednez","year":"2015","journal-title":"Artif Intell Med"},{"key":"2021032314263124600_ref53","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.3390\/ijms20184331","article-title":"Molecular docking: shifting paradigms in drug discovery","volume":"20","author":"Pinzi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2021032314263124600_ref54","article-title":"Molecular docking: a structure-based approach for drug repurposing","author":"Kumar","journal-title":"In Silico Drug Design. Repurposing Techniques and Methodologies"},{"key":"2021032314263124600_ref55","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.2174\/156802611795860951","article-title":"Homology models in docking and high-throughput docking","volume":"11","author":"Cavasotto","year":"2011","journal-title":"Curr Top Med Chem"},{"key":"2021032314263124600_ref56","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nsb1203-980","article-title":"Announcing the worldwide Protein Data Bank","volume":"10","author":"Berman","year":"2003","journal-title":"Nat Struct Biol"},{"key":"2021032314263124600_ref57","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/med.20067","article-title":"Combining docking and molecular dy-namic simulations in drug design","volume":"26","author":"Alonso","year":"2006","journal-title":"Med Res Rev"},{"key":"2021032314263124600_ref58","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","article-title":"ZINC 15\u2013ligand discovery for everyone","volume":"55","author":"Sterling","year":"2015","journal-title":"J Chem Inf Model"},{"key":"2021032314263124600_ref59","doi-asserted-by":"crossref","first-page":"D1102","DOI":"10.1093\/nar\/gky1033","article-title":"PubChem 2019 update: improved access to chemical data","volume":"47","author":"Kim","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2021032314263124600_ref60","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2021032314263124600_ref61","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/acsmedchemlett.7b00462","article-title":"Data sets representative of the structures and experimental properties of FDA-approved drugs","volume":"9","author":"Douguet","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"2021032314263124600_ref62","doi-asserted-by":"crossref","first-page":"D1137","DOI":"10.1093\/nar\/gkx1088","article-title":"SuperDRUG2: a one stop resource for approved\/marketed drugs","volume":"46","author":"Siramshetty","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2021032314263124600_ref63","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gky1075","article-title":"ChEMBL: towards direct deposition of bioassay data","volume":"47","author":"Mendez","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2021032314263124600_ref64","doi-asserted-by":"crossref","first-page":"D109","DOI":"10.1093\/nar\/gkr988","article-title":"KEGG for integration and interpretation of large-scale molecular data sets","volume":"40","author":"Kanehisa","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"2021032314263124600_ref65","doi-asserted-by":"crossref","first-page":"W448","DOI":"10.1093\/nar\/gkv306","article-title":"MTiOpenScreen: a web server for structure-based virtual screening","volume":"43","author":"Labb\u00e9","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2021032314263124600_ref66","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The Drug Repurposing Hub: a next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat Med"},{"key":"2021032314263124600_ref67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1758790","article-title":"Moroccan medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations","author":"Aanouz","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1782768","article-title":"Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro","author":"Alamri","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1786459","article-title":"Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study","author":"Ancy","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1779819","article-title":"Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target","author":"Arun","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref71","doi-asserted-by":"crossref","first-page":"118080","DOI":"10.1016\/j.lfs.2020.118080","article-title":"Computational insights into tetracyclines as inhibitors against SARS-CoV-2 Mpro via combinatorial molecular simulation calculations","volume":"257","author":"Bharadwaj","year":"2020","journal-title":"Life Sci"},{"key":"2021032314263124600_ref72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1763201","article-title":"An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study","author":"Das","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref73","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.3390\/ijms21103626","article-title":"Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds","volume":"21","author":"Fischer","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2021032314263124600_ref74","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.3390\/ijms21113793","article-title":"Prediction of novel inhibitors of the main protease (M-pro) of SARS-CoV-2 through consensus docking and drug reposition","volume":"21","author":"Gimeno","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2021032314263124600_ref75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1764868","article-title":"Potential inhibitors of corona-virus 3-chymotrypsin-like protease (3CLpro): an in silico screening of alkaloids and terpenoids from African medicinal plants","author":"Gyebi","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref76","doi-asserted-by":"crossref","first-page":"117963","DOI":"10.1016\/j.lfs.2020.117963","article-title":"Virtual screening, ADME\/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19","volume":"256","author":"Hage-Melim","year":"2020","journal-title":"Life Sci"},{"key":"2021032314263124600_ref77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1761883","article-title":"A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2","author":"Islam","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref78","doi-asserted-by":"crossref","first-page":"107325","DOI":"10.1016\/j.compbiolchem.2020.107325","article-title":"Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors","volume":"88","author":"Jim\u00e9nez-Alberto","year":"2020","journal-title":"Comput Biol Chem"},{"key":"2021032314263124600_ref79","doi-asserted-by":"crossref","first-page":"117627","DOI":"10.1016\/j.lfs.2020.117627","article-title":"Virtual screening and repurposing of FDA ap-proved drugs against COVID-19 main protease","volume":"251","author":"Kandeel","year":"2020","journal-title":"Life Sci"},{"key":"2021032314263124600_ref80","first-page":"1","article-title":"Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach","author":"Khan","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1792344","article-title":"Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CLpro)","author":"Koulgi","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref82","first-page":"S1876","article-title":"In silico prediction of potential inhibitors for the Main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing","author":"Kumar","year":"2020","journal-title":"J Infect Public Health"},{"key":"2021032314263124600_ref83","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1093\/bioinformatics\/btaa224","article-title":"Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus","volume":"36","author":"Liu","year":"2020","journal-title":"Bioinformatics."},{"key":"2021032314263124600_ref84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1764393","article-title":"FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication","author":"Lobo-Galo","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref85","first-page":"1","article-title":"Molecular docking and simulation studies on SARS-CoV-2 Mpro reveals Mitoxantrone, Leucovorin, Birinapant, and Dynasore as potent drugs against COVID-19","author":"Lokhande","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref86","first-page":"1","article-title":"Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach","author":"Mittal","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1752802","article-title":"Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19","author":"Muralidharan","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref88","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1021\/acs.biochem.0c00160","article-title":"Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms","volume":"59","author":"Nutho","year":"2020","journal-title":"Biochemistry"},{"key":"2021032314263124600_ref89","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25143193","article-title":"High throughput virtual screening to discover inhibitors of the main protease of the coronavirus SARS-CoV-2","volume":"25","author":"Olubiyi","year":"2020","journal-title":"Molecules"},{"key":"2021032314263124600_ref90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1757510","article-title":"Peptide-like and small-molecule inhibitors against Covid-19","author":"Pant","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref91","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25173830","article-title":"Drug repurposing for candidate SARS-CoV-2 main protease inhibitors by a novel in silico method","volume":"25","author":"Sencanski","year":"2020","journal-title":"Molecules"},{"key":"2021032314263124600_ref92","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20201256","article-title":"Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy","volume":"40","author":"Shamsi","year":"2020","journal-title":"Biosci Rep"},{"key":"2021032314263124600_ref93","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/2211-5463.12875","article-title":"Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease","volume":"10","author":"Tsuji","year":"2020","journal-title":"FEBS Open Bio"},{"key":"2021032314263124600_ref94","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jpha.2020.03.009","article-title":"Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants","volume":"10","author":"ul Qamar","year":"2020","journal-title":"J Pharm Anal"},{"key":"2021032314263124600_ref95","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1021\/acs.jcim.0c00179","article-title":"Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study","volume":"60","author":"Wang","year":"2020","journal-title":"J Chem Inf Model"},{"key":"2021032314263124600_ref96","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.3390\/ijms21093099","article-title":"Structural and evolutionary analysis indicate that the SARS-CoV-2 Mpro is a challenging target for small-molecule inhibitor design","volume":"21","author":"Bz\u00f3wka","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2021032314263124600_ref97","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nature12711","article-title":"Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor","volume":"503","author":"Ge","year":"2013","journal-title":"Nature"},{"key":"2021032314263124600_ref98","doi-asserted-by":"crossref","first-page":"105465","DOI":"10.1016\/j.ejps.2020.105465","article-title":"A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection","volume":"153","author":"Abo-Zeid","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"2021032314263124600_ref99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1772885","article-title":"Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening","author":"de Oliveira","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref100","doi-asserted-by":"crossref","DOI":"10.1186\/s12860-020-00294-x","article-title":"Identification of a druggable binding pocket in the spike protein reveals a key site for existing drugs potentially capable of com-bating Covid-19 infectivity","volume":"21","author":"Drew","year":"2020","journal-title":"BMC Mol Cell Biol"},{"key":"2021032314263124600_ref101","doi-asserted-by":"crossref","first-page":"105960","DOI":"10.1016\/j.ijantimicag.2020.105960","article-title":"Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloro-quine against SARS-CoV-2 infection","volume":"55","author":"Fantini","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2021032314263124600_ref102","doi-asserted-by":"crossref","first-page":"104419","DOI":"10.1016\/j.meegid.2020.104419","article-title":"Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein","volume":"85","author":"Feng","year":"2020","journal-title":"Infect Genet Evol"},{"key":"2021032314263124600_ref103","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s11655-020-3427-6","article-title":"In silico screening of potential spike gly-coprotein inhibitors of SARS-CoV-2 with drug repurposing strategy","volume":"26","author":"Wei","year":"2020","journal-title":"Chin J Integr Med"},{"key":"2021032314263124600_ref104","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3906\/biy-2005-112","article-title":"Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target","volume":"44","author":"DurdaGi","year":"2020","journal-title":"Turk J Biol"},{"key":"2021032314263124600_ref105","doi-asserted-by":"crossref","first-page":"105495","DOI":"10.1016\/j.ejps.2020.105495","article-title":"Structure-based drug repo-sitioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages","volume":"153","author":"Singh","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"2021032314263124600_ref106","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12967-020-02439-0","article-title":"Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach","volume":"18","author":"Aftab","year":"2020","journal-title":"J Transl Med"},{"key":"2021032314263124600_ref107","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e04502","article-title":"SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a drug repurposing study","volume":"6","author":"Ahmad","year":"2020","journal-title":"Heliyon"},{"key":"2021032314263124600_ref108","doi-asserted-by":"publisher","DOI":"10.1016\/j.mjafi.2020.05.005","article-title":"Evaluating the potential of different inhibitors on RNA-dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2: a molecular modeling approach","author":"Choudhury","year":"2020","journal-title":"Med J Armed Forces India"},{"key":"2021032314263124600_ref109","doi-asserted-by":"crossref","first-page":"117477","DOI":"10.1016\/j.lfs.2020.117477","article-title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19","volume":"248","author":"Elfiky","year":"2020","journal-title":"Life Sci"},{"key":"2021032314263124600_ref110","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"2021032314263124600_ref111","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3389\/fphar.2020.01196","article-title":"COVID-19 therapeutic options under investigation","volume":"11","author":"Kaddoura","year":"2020","journal-title":"Front Pharmacol"},{"key":"2021032314263124600_ref112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1784291","article-title":"Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease","author":"Kandeel","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref113","first-page":"1","article-title":"Virtual screening and dynamics of potential inhibitors targeting RNA binding domain of nucleocapsid phosphoprotein from SARS-CoV-2","author":"Yadav","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref114","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3390\/v12050525","article-title":"Potential drugs targeting early innate immune evasion of SARS-coronavirus 2 via 2-O-methylation of viral RNA","volume":"12","author":"Encinar","year":"2020","journal-title":"Viruses"},{"key":"2021032314263124600_ref115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1779133","article-title":"Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study","author":"Tazikeh-Lemeski","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref116","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.drudis.2020.03.019","article-title":"D\u00e9j\u00e0 vu: Stimulating open drug discovery for SARS-CoV-2","volume":"25","author":"Ekins","year":"2020","journal-title":"Drug Discov Today"},{"key":"2021032314263124600_ref117","first-page":"1","article-title":"Drug repurposing for corona-virus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes","author":"Elmezayen","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref118","doi-asserted-by":"crossref","first-page":"103848","DOI":"10.1016\/j.compbiomed.2020.103848","article-title":"Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach","volume":"122","author":"Iftikhar","year":"2020","journal-title":"Comput Biol Med"},{"key":"2021032314263124600_ref119","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.joim.2020.02.005","article-title":"In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus","volume":"18","author":"Zhang","year":"2020","journal-title":"J Integr Med"},{"key":"2021032314263124600_ref120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1762741","article-title":"An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets","author":"Sinha","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"2021032314263124600_ref121","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/1873-3468.13806","article-title":"Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs","volume":"594","author":"Hijikata","year":"2020","journal-title":"FEBS Lett"},{"key":"2021032314263124600_ref122","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"2021032314263124600_ref123","first-page":"1","article-title":"Drug repurposing using computational methods to identify therapeutic options for COVID-19","author":"Mahdian","year":"2020","journal-title":"J Diabetes Metab Disord"},{"key":"2021032314263124600_ref124","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3389\/fmicb.2020.01796","article-title":"Quinolines-based SARS-CoV-2 3CLpro and RdRp inhibitors and Spike-RBD-ACE2 inhibitor for drug-repurposing against COVID-19: an in silico analysis","volume":"11","author":"Alexpandi","year":"2020","journal-title":"Front Microbiol"},{"key":"2021032314263124600_ref125","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"2021032314263124600_ref126","doi-asserted-by":"crossref","first-page":"106080","DOI":"10.1016\/j.ijantimicag.2020.106080","article-title":"COVID-19 treatment: close to a Cure? A rapid review of pharmacotherapies for the novel coronavirus","volume":"56","author":"Song","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2021032314263124600_ref127","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"2021032314263124600_ref128","doi-asserted-by":"crossref","DOI":"10.7861\/clinmed.2020-0129","article-title":"Chloroquine and COVID-19 - a potential game changer?","author":"Sturrock","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"2021032314263124600_ref129","doi-asserted-by":"crossref","DOI":"10.1097\/BOR.0000000000000731","article-title":"Role for antimalarials in the management of COVID-19","author":"Schrezenmeier","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"2021032314263124600_ref130","doi-asserted-by":"crossref","DOI":"10.1016\/j.apsb.2020.04.006","article-title":"D3Targets-2019-nCoV: a webserver for pre-dicting drug targets and for multi-target and multi-site based virtual screening against COVID-19","author":"Shi","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"2021032314263124600_ref131","doi-asserted-by":"crossref","DOI":"10.1016\/j.bj.2020.05.001","article-title":"Artificial intelligence approach fighting COVID-19 with repurposing drugs","author":"Ke","year":"2020","journal-title":"Biomed J"},{"key":"2021032314263124600_ref132","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","article-title":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model","volume":"18","author":"Beck","year":"2020","journal-title":"Comput Struct Biotechnol J"},{"key":"2021032314263124600_ref133","first-page":"230","article-title":"Self-attention based molecule representation for predicting drug-target interaction","volume":"106","author":"Shin","year":"2019","journal-title":"Proc Mach Learn Res"},{"key":"2021032314263124600_ref134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/database\/bay083","article-title":"Drug Target Commons 2.0: a community platform for systematic analysis of drug-target interaction profiles","volume":"2018","author":"Tanoli","year":"2018","journal-title":"Database (Oxford)"},{"key":"2021032314263124600_ref135","doi-asserted-by":"crossref","first-page":"D198","DOI":"10.1093\/nar\/gkl999","article-title":"BindingDB: a web-accessible database of exper-imentally determined protein-ligand binding affinities","volume":"35","author":"Liu","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"2021032314263124600_ref136","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"key":"2021032314263124600_ref137","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41562-020-0911-0","article-title":"Pandemic publishing poses a new COVID-19 challenge","volume":"4","author":"Palayew","year":"2020","journal-title":"Nat Hum Behav"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/22\/2\/726\/36653985\/bbaa288.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/22\/2\/726\/36653985\/bbaa288.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T07:14:39Z","timestamp":1698218079000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/22\/2\/726\/5956159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":137,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,11,5]]},"published-print":{"date-parts":[[2021,3,22]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbaa288","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2020,11,5]]}}}